Oleksandr Koniev

Oleksandr Koniev

Auto-generated profile, based on publicly available information

Oleksandr Koniev

Syndivia SAS, 8 allée Gaspard Monge, Strasbourg 67000, France

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2019 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
IDIgor Dovgan
Igor Dovgan
OKOleksandr Koniev
Oleksandr Koniev
SKSergii Kolodych
Sergii Kolodych
AWAlain Wagner
Alain Wagner

30 June 2016 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
RARiyadh Ahmed Atto Al‐Shuaeeb
Riyadh Ahmed Atto Al‐Shuaeeb
SKSergii Kolodych
Sergii Kolodych
OKOleksandr Koniev
Oleksandr Koniev
SDSébastien Delacroix
Sébastien Delacroix
SEStéphane Erb
Stéphane Erb
SMSamir Messaoudi
Samir Messaoudi

2 January 2025 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
FEFerran Esteve
Ferran Esteve
JSJean-Louis SCHMITT
Jean-Louis SCHMITT
SKSergii Kolodych
Sergii Kolodych
OKOleksandr Koniev
Oleksandr Koniev
JLJean-Marie Lehn
Jean-Marie Lehn

19 April 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
MBManuela Bratti
Manuela Bratti
ESElisa Stubbs
Elisa Stubbs
SKSergii Kolodych
Sergii Kolodych
HSHerve Souchet
Herve Souchet
LKLois Kelly
Lois Kelly
PLPierre Launay
Pierre Launay
Innovative strategies for enhancing efficacy and overcoming drug resistance in hematologic cancers, such as using antibody–drug conjugates (ADC), have shifted the paradigm of conventional care by delivering promising outcomes in cancer therapies with a significant reduction in the risk of relapse. Transferrin receptor (TfR1), cluster of differentiation 71 (CD71), is known to be overexpressed in malignant cells and considered a potent antitumor target. Therefore, we developed an anti-CD71 ADC, INA03, a humanized antibody conjugated to monomethyl auristatin E through a 3-arylpropiolonitrile–valine–citrulline linker. In this study, we investigated the potency and safety of INA03, in competition with Transferrin (Tf), the CD71’s natural ligand, as a novel strategy to specifically target highly proliferative cells. The high expression of CD71 was confirmed on different leukemic cell lines, allowing INA03 to bind efficiently. Subsequently, INA03 rapidly internalizes into lysosomal compartments, in which its cytotoxic drug is released following cathepsin B cleavage. Downregulation of CD71 expression using shRNA highlighted that INA03-induced cell death was dependent on CD71 density at the cell surface. INA03 intravenous treatment in acute leukemia mouse models significantly reduced tumor burden, increased mouse survival, and showed no residual disease compared with conventional chemotherapies. Because INA03 competes with human Tf, a double knock-in (human CD71/human Tf) competent mouse model was generated to mimic human pharmacokinetics and pharmacodynamics. INA03 administration in human CD71/hTf mice did not reveal any improper toxicities, even at high doses. Hence, these data demonstrate the promising preclinical efficacy and safety of INA03 and support its development as a novel acute leukemia treatment. Significance: The Tf receptor is believed to be undruggable because of its ubiquitous expression. By entering into competition with its cognate ligand, the Tf and INA03 ADC can safely achieve potency.

13 October 2025 in Biomacromolecules
Verified
Journal Article
Closed access
VLVictor Lehot
Victor Lehot
OLOndřej Lidický
Ondřej Lidický
JMJulien Most
Julien Most
MNMarc Nothisen
Marc Nothisen
SEStéphane Erb
Stéphane Erb
AWAlain Wagner
Alain Wagner

19 October 2023 in ACS Omega
Verified
Journal Article
Open access
VLVictor Lehot
Victor Lehot
OLOndřej Lidický
Ondřej Lidický
JMJulien Most
Julien Most
SEStéphane Erb
Stéphane Erb
IDIgor Dovgan
Igor Dovgan
AWAlain Wagner
Alain Wagner
Protein conjugates have found applications in a wide variety of fields, ranging from therapeutics to imaging and detection. However, robust control over the parameters of the conjugation process (such as sites and degree of conjugation) remains challenging. Previously, our group introduced Equimolar NAtive Chemical Tagging (ENACT), a method which allows for the monofunctionalization of proteins by combining an iterative low-conversion bioconjugation, an automated process, and a bioorthogonal trans-tagging reaction. However, while the automated ENACT was dimensioned to achieve monoconjugation at the mg scale, in early stage research, because of the rarity and cost of the starting materials, it is often necessary to prepare conjugates at the lower, μg, scale. Here, we introduce modified ENACT protocols, as well as a new ENACT conjugation reagent, which allow for the monofunctionalization of proteins on the micrograms scale, using minimal quantities of payload.